Prostate Cancer Clinical Trials in Denver

Showing 121-140 of 269 trials

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

NCT04249947

An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.

Prostatic Neoplasms, Castration-ResistantNeoplasms by Histologic TypeNeoplasms, Prostate+14 more

Poseida Therapeutics, Inc.40 participantsStarted Feb 2020

Duarte, California, United States • San Diego, California, United States • San Francisco, California, United States +7 more locations

TERMINATEDPhase 1< 1 mile

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT05241613

This clinical trial is evaluating a drug called AC176 in participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least two prior systemic therapies. The main goals of this study are to: * Identify the recommended dose of AC176 that can be given safely to participants * Evaluate the side effects of AC176 * Evaluate pharmacokinetics of AC176 * Evaluate the effectiveness of AC176

Metastatic Castration Resistant Prostate Cancer

Accutar Biotechnology Inc28 participantsStarted Mar 2022

Denver, Colorado, United States • Sarasota, Florida, United States • Detroit, Michigan, United States +2 more locations

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Prostate Cancer Trials in Other Cities

A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance

INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4)

Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer

Stockholm3 Validation Study in a Multi-Ethnic Cohort

BioProtect Balloon Implant™ Balloon System Pivotal Study BP-007

ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

Other Conditions in Denver